Effect of pentobarbital and urethane on the release of hypothalamic somatostatin and pituitary growth hormone.
Hypothalamic somatostatin release was investigated in the rat to elucidate the mechanism of anesthetic action on growth hormone (GH) release from the pituitary. Intraperitoneal injection of sodium pentobarbital (5 mg/100 gm B.W.) significantly elevated serum GH levels and increased hypothalamic somatostatin concentration from basal values of 0.98 +/- 0.01 to 1.21 +/- 0.06 ng/mg wet wt. In contrast, urethane (150 mg/100 gm B.W., IP) administration lowered serum GH levels and hypothalamic somatostatin concentration (0.64 +/- 0.04 ng/mg wet wt.). However, the mean concentration of pancreatic somatostatin showed no change in either case. In rats receiving passive immunization with 0.5 ml rabbit antiserum to somatostatin (SRIF-AS), serum GH levels were significantly increased (67.5 +/- 12.3 ng/ml) and did not differ from those in the group treated with normal rabbit serum (NRS) plus pentobarbital (101.3 +/- 18.5 ng/ml). However, serum GH levels in rats injected with SRIF-AS plus pentobarbital were increased to higher values than in rats given SRIF-AS alone. When urethane was administered to rats after passive immunization with SRIF-AS, urethane-induced suppression of serum GH levels was markedly inhibited (5.5 +/- 2.0 vs. 33.5 +/- 7.5 ng/ml). These results suggest a possibility that the changes in serum GH levels observed with pentobarbital or urethane administration may be induced at least in one part by somatostatin released from the hypothalamus.
D000818:Animals; D013006:Growth Hormone / Q000097:blood*; D007031:Hypothalamus / Q000378:metabolism*; D007116:Immunization, Passive; D008297:Male; D010179:Pancreas / Q000378:metabolism; D010424:Pentobarbital / Q000494:pharmacology*; D051381:Rats; D013004:Somatostatin / Q000097:blood* / Q000276:immunology; D014520:Urethane / Q000494:pharmacology*
D014520:Urethane; D013004:Somatostatin; D013006:Growth Hormone; D010424:Pentobarbital